お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
972331

CART細胞治療薬の世界市場 (2020-2030年):製品・機序・用途・標的抗原・国別分析・競合情勢

Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 266 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
CART細胞治療薬の世界市場 (2020-2030年):製品・機序・用途・標的抗原・国別分析・競合情勢
出版日: 2020年11月23日
発行: BIS Research Inc.
ページ情報: 英文 266 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCART細胞治療薬の市場規模は予測期間中44.79%のCAGRで成長すると予測されています。老齢人口の増加、リンパ腫および白血病の症例数の増加、化学療法や放射線療法などの代替療法では奏効しない再発・難治性の癌症例の増加、新規免疫療法のR&Dへの注力、強力な製品パイプラインなどの要因が同市場の成長を推進しています。

当レポートでは、世界のCART細胞治療薬の市場を調査し、市場および技術の定義・概要、現在の上市済み薬およびパイプライン薬のプロファイル、特許情勢、法的枠組み、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、適応症・標的抗原・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 技術の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

  • 開発タイムライン
  • 市場成長の可能性
  • 臨床試験

第5章 世界市場の規模・予測

  • 上市済み薬
    • Tisagenlecleucel (Kymriah)
    • Axicabtagene Ciloleucel(Yescarta)
    • Brexucabtagene Autoleucel(Tecartus)
  • パイプライン薬
    • BB2121(Idecaptagene Cicleucel)
    • JCAR017(Lisocabtagene Maraleucel)
    • KTE-C19(Axicabtagene Ciloleucel)
    • CTL019(Tisagenlecleucel)
    • JNJ-68284528
  • COVID-19の影響

第6章 特許情勢

第7章 CART細胞治療薬:疫学

  • 概要
  • 副作用
  • 副作用の管理

第8章 産業考察

  • 概要
  • 関連規制シナリオ
  • 法的要件・枠組み:米国
  • 法的要件・枠組み:欧州
  • 法的要件・枠組み:アジア太平洋
  • 世界の迅速指定
  • 薬価
  • 償還

第9章 CART細胞治療薬の開発・製造

  • 概要
  • CART細胞治療薬の課題
    • 治療薬の承認
    • 製造品質管理
    • 有効性と質調整生存年(QALY)評価
    • 安全性評価
    • 価格・患者アクセス
    • 償還

第10章 市場力学

  • 影響分析
  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第11章 市場分析・予測:用途別

  • 概要
  • びまん性大細胞型B細胞リンパ腫(DLBCL)
  • 急性リンパ芽球性白血病(ALL)
  • 多発性骨髄腫(MM)
  • 慢性リンパ性白血病(CLL)
  • 濾胞性リンパ腫(FL)
  • マントル細胞リンパ腫(MCL)
  • その他

第12章 市場分析・予測:標的抗原別

  • 概要
  • CD19/CD22
  • BCMA(B細胞成熟抗原)
  • その他

第13章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第14章 競合情勢

  • 主な展開・戦略
  • 市場シェア分析

第15章 企業プロファイル

  • Amgen, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird Bio Inc
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics, Ltd.
  • Cartesian Therapeutics, Inc.
  • Cellectis S.A.
  • Celyad Oncology SA
  • Fortress Biotech, Inc
  • Janssen Pharmaceuticals, Inc.
  • Kite Pharma, Inc (A Gilead Company)
  • Legend Biotech Corporation
  • Novartis AG
  • Pfizer Inc.
図表

List of Tables

  • Table 1: Leading Players in Global CAR T-Cell Therapy Market
  • Table 8.1: History of Regulatory Activities and Tools Applied to Kymriah in U.S. and EU
  • Table 8.2: History of Regulatory Activities and Tools Applied to Yescarta in U.S. and EU
  • Table 8.3: Expedited Regulatory Designations Around the World
  • Table 10.1: Cytokine Release Syndrome (CRS) Grading Systems
  • Table 15.1: Amgen, Inc.: Pipeline Product Portfolio
  • Table 15.2: Autolus Therapeutics plc: Pipeline Product Portfolio
  • Table 15.3: Bellicum Pharmaceuticals, Inc.: Pipeline Product Portfolio
  • Table 15.4: Bluebird Bio Inc Company: Pipeline Product Portfolio
  • Table 15.5: Bristol Myers Squibb Company: Pipeline Product Portfolio
  • Table 15.6: CARsgen Therapeutics, Ltd Company: Pipeline Product Portfolio
  • Table 15.7: Cartesian Therapeutics, Inc.: Pipeline Product Portfolio
  • Table 15.8: Celyad Oncology SA Company: Pipeline Product Portfolio
  • Table 15.9: Fortress Biotech, Inc: Pipeline Product Portfolio
  • Table 15.10: Janssen Pharmaceuticals, Inc Company: Pipeline Product Portfolio
  • Table 15.11: Kite Pharma, Inc: Pipeline Product Portfolio
  • Table 15.12: Legend Biotech Corporation, Company: Pipeline Product Portfolio
  • Table 15.13: Novartis AG: Pipeline Product Portfolio
  • Table 15.14: Pfizer Plc: Pipeline Product Portfolio

List of Figures

  • Figure 1: Global Prevalence of Hematologic Malignancies, 2018
  • Figure 2: Global Geriatric Population (by Age)
  • Figure 3: Global CAR T-Cell Therapy Clinical Trials (by Region)
  • Figure 4: Global CAR T-Cell Therapy Market
  • Figure 5: Global CAR T-Cell Therapy: Impact Analysis
  • Figure 6: Share of Key Developments and Strategies, June 2015-June 2020
  • Figure 7: Global CAR T-Cell Therapy Market (by Application), 2019 and 2030
  • Figure 8: Global CAR T-Cell Therapy Market (by Target Antigen), 2019 and 2030
  • Figure 9: Global CAR T-Cell Therapy Market (by Region), 2019 and 2030
  • Figure 2.1: Global CAR T-Cell Therapy Market Segmentation
  • Figure 3.1: Global CAR T-Cell Therapy Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Timeline of CAR T-Cell Therapy Development (Year-Wise Analysis)
  • Figure 4.2: CAR T-Cell Therapy Market Revenue (by Region), 2019 and 2030
  • Figure 4.3: Global CAR T-Cell Therapy Clinical Trials (by Region)
  • Figure 4.4: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials - U.S.
  • Figure 4.5: Global CAR T-Cell Therapy Clinical Trials (by Phase)
  • Figure 4.6: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials - China
  • Figure 4.7: CAR T-Cell Therapy Clinical Trials in China (by Region)
  • Figure 4.8: CAR T-Cell Therapy Clinical Trials (by Phase)
  • Figure 4.9: CAR T-Cell Therapy Clinical Trials - Rest-of-the-World (by Phase)
  • Figure 4.10: Global CAR T-Cell Therapy Clinical Trials (by Phase)
  • Figure 5.1: Global CAR T-Cell Therapy Market (Kymriah - Product Revenue), 2019-2030
  • Figure 5.2: Global CAR T-Cell Therapy Market (Yescarta - Product Revenue), 2019-2030
  • Figure 5.3: Global CAR T-Cell Therapy Market (Tecartus - Product Revenue), 2020-2030
  • Figure 5.4: Global CAR T-Cell Therapy Market (Idecaptagene Cicleucel - Product Revenue)
  • Figure 5.5: Global CAR T-Cell Therapy Market (Lisocabtagene Maraleucel - Product Revenue)
  • Figure 5.6: Global CAR T-Cell Therapy Market (Axicabtagene Ciloleucel - Product Revenue)
  • Figure 5.7: Global CAR T-Cell Therapy Market (Tisagenlecleucel - Product Revenue)
  • Figure 5.8: Global CAR T-Cell Therapy Market (JNJ-68284528 - Product Revenue)
  • Figure 5.9: COVID-19 Status Globally
  • Figure 5.10: COVID-19 Progression Curve
  • Figure 5.11: Most Impacted Practices in CAR T-Cell Therapy
  • Figure 5.12: COVID-19 Impact on the CAR T-Cell Therapy Market
  • Figure 5.13: Impact of COVID-19 on Clinical Trials
  • Figure 5.14: Status of Clinical Trials
  • Figure 5.15: Disrupted Clinical Trials by Phase of Clinical Trial
  • Figure 5.16: Disrupted Clinical Trials by Therapy Area
  • Figure 5.17: Major Areas of Disruption
  • Figure 5.18: Diagnosis Rates of Various Cancer During Pandemic
  • Figure 5.19: Key Areas of Disruption in Commercial Operations
  • Figure 6.1: CAR T-Cell Therapy Patent Activity Ratio (by Region)
  • Figure 6.2: CAR T-Cell Therapy Patents (by Jurisdictions)
  • Figure 6.3: U.S. Patent Activity: Chimeric Antigen Receptor (Patents by Year)
  • Figure 7.1: Global Prevalence of Hematologic Malignancies , 2018
  • Figure 7.2: Estimated Incident Cases of Hematologic Malignancies in the U.S. (Total Population)
  • Figure 7.3: Estimated Incident Cases of Hematologic Malignancies in Canada (Total Population)
  • Figure 7.4: Estimated Incident Cases of Hematologic Malignancies in Germany (Total Population)
  • Figure 7.5: Estimated Incident Cases of Hematologic Malignancies in France (Total Population)
  • Figure 7.6: Estimated Incident Cases of Hematologic Malignancies in Italy (Total Population)
  • Figure 7.7: Estimated Incident Cases of Hematologic Malignancies in Spain (Total Population)
  • Figure 7.8: Estimated Incident Cases of Hematologic Malignancies in the U.K. (Total Population)
  • Figure 7.9: Estimated Incident Cases of Hematologic Malignancies in Japan (Total Population)
  • Figure 7.10: Estimated Incident Cases of Hematologic Malignancies in Australia (Total Population)
  • Figure 7.11: Grading System for Management of CAT T-Cell Toxicities
  • Figure 8.1: Regulatory Strategy for CAR T-Cell Therapy in U.S
  • Figure 8.2: Steps for Obtaining Marketing Authorization
  • Figure 8.3: USFDA Review Timeline
  • Figure 8.4: Regulatory Strategy for CAR T-Cell Therapy in EU
  • Figure 8.5: EMA Review Timeline
  • Figure 10.1: Global CAR T-Cell Therapy: Impact Analysis
  • Figure 10.2: Estimated Cases of Hematologic Malignancies in U.S., 2020
  • Figure 10.3: Estimated Number of Hematologic Malignancies, 2018 and 2030
  • Figure 10.4: Number of Clinical Trial, 2015-2020
  • Figure 10.5: Global CAR T-Cell Therapy Market, 2017-2019
  • Figure 10.6: CAR T-Cell Research Activity, 2018
  • Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030
  • Figure 11.2: Global CAR T-Cell Therapy Market (for DLBCL), 2019-2030
  • Figure 11.3: Global CAR T-Cell Therapy Market (for ALL), 2019-2030
  • Figure 11.4: Global CAR T-Cell Therapy Market (for MM), 2019-2030
  • Figure 11.5: Global CAR T-Cell Therapy Market (for CLL), 2019-2030
  • Figure 11.6: Global CAR T-Cell Therapy Market (for FL), 2019-2030
  • Figure 11.7: Global CAR T-Cell Therapy Market (for MCL), 2019-2030
  • Figure 11.8: Global CAR T-Cell Therapy Market (for Others), 2019-2030
  • Figure 12.1: Global CAR T-Cell Therapy Market (by Target Antigen)
  • Figure 12.2: Global CAR T-Cell Therapy Market (for CD19/CD22), 2019-2030
  • Figure 12.3: Global CAR T-Cell Therapy Market (for BCMA), 2019-2030
  • Figure 12.4: Global CAR T-Cell Therapy Market (for Other Antigens), 2019-2030
  • Figure 13.1: Global CAR T-Cell Therapy Market (by Region)
  • Figure 13.2: Global CAR T-Cell Therapy Market (by Region), 2019-2030
  • Figure 13.3: North America CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: Revenue Contributions of Various Countries in North America, 2019 and 2030
  • Figure 13.6: U.S. CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.7: U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.8: Canada CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.9: Canada CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.10: Europe CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.11: Europe: Market Dynamics
  • Figure 13.12: Revenue Contributions of Various Countries in Europe, 2019 and 2030
  • Figure 13.13: Germany CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.14: Germany CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.15: U.K. CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.16: U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.17: France CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.18: France CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.19: Italy CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.20: Italy CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.21: Spain CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.22: Spain CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.23: Rest-of-Europe CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.24: Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.25: Asia-Pacific CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.26: Asia-Pacific: Market Dynamics
  • Figure 13.27: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030
  • Figure 13.28: Japan CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.29: Japan CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.30: Australia CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.31: Australia CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.32: Rest-of-APAC CAR T-Cell Therapy Market, 2019-2030
  • Figure 13.33: Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
  • Figure 13.34: Latin America: Market Dynamics
  • Figure 13.35: RoW CAR T-cell therapy market, 2019-2030
  • Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
  • Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
  • Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
  • Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
  • Figure 14.5: Market Share Analysis (by Company), 2018 and 2019
  • Figure 15.1: Total Number of Companies Profiled
  • Figure 15.2: Amgen, Inc.: Overall Financials, 2017-2019
  • Figure 15.3: Amgen, Inc.: Sales (by Product), 2017-2019
  • Figure 15.4: Amgen, Inc.: Revenue (by Region), 2017-2019
  • Figure 15.5: Amgen, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.6: Amgen, Inc.: SWOT Analysis
  • Figure 15.7: Autolus Therapeutics plc: Overall Financials, 2017-2019
  • Figure 15.8: Autolus Therapeutics plc: R&D Expenditure, 2017-2019
  • Figure 15.9: Autolus Therapeutics plc: SWOT Analysis
  • Figure 15.10: Bellicum Pharmaceuticals, Inc.: Overall Financials, 2017-2019
  • Figure 15.11: Bellicum Pharmaceuticals, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.12: Bellicum Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 15.13: Bluebird Bio Inc: Overall Financials, 2017-2019
  • Figure 15.14: Bluebird Bio Inc: R&D Expenditure, 2017-2019
  • Figure 15.15: Bluebird Bio Inc: SWOT Analysis
  • Figure 15.16: Bristol Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 15.17: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
  • Figure 15.18: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
  • Figure 15.19: Bristol Myers Squibb Company: SWOT Analysis
  • Figure 15.20: CARsgen Therapeutics, Ltd.: SWOT Analysis
  • Figure 15.21: Cartesian Therapeutics, Inc: SWOT Analysis
  • Figure 15.22: Cellectis S.A.: Overall Financials, 2017-2019
  • Figure 15.23: Cellectis S.A.: Revenue (by Segment), 2017-2019
  • Figure 15.24: Cellectis S.A.: Revenue (by Region), 2017-2019
  • Figure 15.25: Cellectis S.A.: R&D Expenditure, 2017-2019
  • Figure 15.26: Cellectis S.A.: SWOT Analysis
  • Figure 15.27: Celyad Oncology SA: Overall Financials, 2017-2019
  • Figure 15.28: Celyad Oncology SA: Revenue (by Segment), 2018-2019
  • Figure 15.29: Celyad Oncology SA: R&D Expenditure, 2017-2019
  • Figure 15.30: Celyad Oncology SA: SWOT Analysis
  • Figure 15.31: Fortress Biotech, Inc: Overall Financials, 2017-2019
  • Figure 15.32: Fortress Biotech, Inc: Revenue (by Segment), 2017-2019
  • Figure 15.33: Fortress Biotech, Inc: R&D Expenditure, 2017-2019
  • Figure 15.34: Fortress Biotech, Inc: SWOT Analysis
  • Figure 15.35: Janssen Pharmaceuticals, Inc: Overall Financials, 2017-2019
  • Figure 15.36: Janssen Pharmaceuticals, Inc: Revenue (by Segment), 2017-2019
  • Figure 15.37: Janssen Pharmaceuticals, Inc: Revenue (by Region), 2017-2019
  • Figure 15.38: Janssen Pharmaceuticals, Inc: R&D Expenditure, 2017-2019
  • Figure 15.39: Janssen Pharmaceuticals, Inc: SWOT Analysis
  • Figure 15.40: Kite Pharma, Inc: Overall Product Portfolio
  • Figure 15.41: Kite Pharma, Inc: Overall Financials, 2017-2019
  • Figure 15.42: Kite Pharma, Inc: Revenue (by Segment), 2017-2019
  • Figure 15.43: Kite Pharma, Inc: Revenue (by Region), 2017-2019
  • Figure 15.44: Kite Pharma, Inc: R&D Expenditure, 2017-2019
  • Figure 15.45: Kite Pharma, Inc: SWOT Analysis
  • Figure 15.46: Legend Biotech Corporation: SWOT Analysis
  • Figure 15.47: Novartis AG: Overall Product Portfolio
  • Figure 15.48: Novartis AG: Overall Financials, 2017-2019
  • Figure 15.49: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 15.50: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 15.51: Novartis AG: R& D Expense, 2017-2019
  • Figure 15.52: Novartis AG: SWOT Analysis
  • Figure 15.53: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 15.54: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.55: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 15.56: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 15.57: Pfizer Inc: R&D Expenditure, 2017-2019
  • Figure 15.58: Pfizer Inc.: SWOT Analysis
目次
Product Code: BHL0987SA

"Global CAR T-Cell Therapy Market to Grow at a CAGR of 44.79% from 2020-2030."

Market Report Coverage - CAR T-Cell Therapy

Market Segmentation

  • Therapy Application - Diffuse large B-cell lymphoma (DLBCL), Acute lymphoblastic leukemia (ALL), Multiple myeloma (MM), Chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), and other cancers or indications
  • Target Antigen - CD19/CD22, BCMA (B-cell maturation antigen), and others target antigens

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Rising Number of Patients with Hematologic Cancers
  • Dramatic Rise in Global CAR T-Cell Trials
  • Landmark Approvals of CAR T-Cell Therapies by the U.S. FDA and the EMA

Market Challenges

  • High Treatment Cost of CAR T-Cell Therapy
  • Side Effects of CAR T-Cell Therapy

Market Opportunities

  • Opportunities for Immunotherapy

Key Companies Profiled

Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.

Key Questions Answered in this Report:

  • What is a CAR T-cell?
  • How are CAR T-cells developed?
  • What are the various indications targeted using CAR T-cell therapies?
  • What are the various CAR T-cell therapies available in the market?
  • What are the emerging CAR T-cell therapies for the treatment of hematologic cancers?
  • How does the pipeline for the global CAR T-cell therapy market look like?
  • What is the current market size and future potential of these CAR T-cell therapies?
  • What are the major market drivers, challenges, and opportunities in the global CAR T-cell therapy market?
  • What is the mechanism of action of various CAR T-cell therapies available in the market?
  • What mechanisms of action and molecules are being trialed the most in pipeline products?
  • What are the target antigens in CAR T-cell therapy?
  • How does the clinical trial landscape look for the global CAR T-cell therapy market?
  • What is the patent landscape of this market? What will be the impact of patent expiry on this market?
  • What is the price structure of CAR T-cell products?
  • What is the total cost of treating a patient with CAR T-cell therapy?
  • What will be the impact of COVID-19 on this market?
  • What are the guidelines implemented by different government bodies to regulate the approval of CAR T-cell therapy?
  • What are the reimbursement scenario and regulatory structure for CAR T-cell therapy?
  • What are the challenges faced by manufacturers in CAR T-cell therapy development?
  • What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
  • Which are the leading players currently holding dominating shares in the global CAR T-cell therapy market?
  • What are the key strategies incorporated by the players of the global CAR T-cell therapy market to sustain the competition and retain their supremacy?
  • What is the current revenue contribution of the global CAR T-cell therapy market (by application type), and how is it expected to evolve in the forecast period?
  • What is the current revenue contribution of the global CAR T-cell therapy market (by target antigen), and how is it expected to evolve in the forecast period?
  • Which region is expected to contribute the highest revenue to the global CAR T-cell therapy market during the forecast period?

Market Overview

The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient's immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications. The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into a significantly higher demand for the CAR T-cell therapy market.

Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy. The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the future.

Within the research report, the market is segmented based on application, target antigen, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CAR T-cell therapy. Due to the diverse product portfolio and intense market penetration, Novartis AG. has been a pioneer in this field and has been a significant competitor in this market.

The pharmaceutical leading manufacturer, Kite Pharma, Inc. (a Gilead Company), has launched its CAR T-cell therapies into the market such as Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel) to compete with Novartis AG's Kymriah (tisagenlecleucel) therapy market dominance.

Based on region, North America holds the largest share of the CAR T-cell therapy market due to improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Technology Definition

  • 1.1 Inclusion and Exclusion Criteria
    • 1.1.1 Inclusions
    • 1.1.2 Exclusions

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 CAR T-Cell Therapy: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Timeline of CAR T-Cell Therapy Development
  • 4.2 CAR T-Cell Therapy Market and Growth Potential, 2019-2030
  • 4.3 CAR T-Cell Therapy and Clinical Trials Landscape
    • 4.3.1 Overview
    • 4.3.2 Clinical Trials in China
    • 4.3.3 Clinical Trials in Rest-of-the-World

5 Global CAR T-Cell Therapy Market, $Million, 2019-2030

  • 5.1 Commercialized Therapeutics
    • 5.1.1 Tisagenlecleucel (Kymriah)
    • 5.1.2 Axicabtagene Ciloleucel (Yescarta)
    • 5.1.3 Brexucabtagene Autoleucel (Tecartus)
  • 5.2 Pipeline Therapeutics
    • 5.2.1 BB2121 (Idecaptagene Cicleucel)
    • 5.2.2 JCAR017 (Lisocabtagene Maraleucel)
    • 5.2.3 KTE-C19 (Axicabtagene Ciloleucel)
    • 5.2.4 CTL019 (Tisagenlecleucel)
    • 5.2.5 JNJ-68284528
  • 5.3 Impact of COVID-19 - CAR T-Cell Therapy
    • 5.3.1 Impact of COVID-19 on Global CAR T-Cell Therapy Market Growth Rate
    • 5.3.2 Clinical Trial Disruptions and Resumptions
    • 5.3.3 COVID-19 Impact on Supply Chain of CAR T-Cell Therapy Market
    • 5.3.4 Reduced Diagnosis of Cancer
    • 5.3.5 Impact on Commercial Operations

6 CAR T-Cell Therapy Patent Landscape

7 Epidemiology of CAR T-Cell Therapy

  • 7.1 Overview
  • 7.2 CAR T-Cell Therapy Side-Effects
    • 7.2.1 Cytokine Release Syndrome (CRS)
    • 7.2.2 CAR T-Cell-Related Encephalopathy Syndrome (CRES)
    • 7.2.3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • 7.3 Management of CAR T-Cell Therapy Side-Effects

8 Industry Insights

  • 8.1 Overview
  • 8.2 Regulatory Scenario of CAR T-Cell Therapy
  • 8.3 Legal Requirements and Frameworks in U.S.
    • 8.3.1 Clinical Trial Authorization
    • 8.3.2 Marketing Authorization
    • 8.3.3 USFDA Guidelines for BLA Submission
    • 8.3.4 Post-Authorization Regulations
  • 8.4 Legal Requirements and Frameworks in Europe
    • 8.4.1 EMA Biologics License Application Process
    • 8.4.2 Centralized Procedure
    • 8.4.3 Decentralized Procedure
    • 8.4.4 Mutual-Recognition Procedure
    • 8.4.5 National Procedure
  • 8.5 Legal Requirements and Frameworks in Asia-Pacific
    • 8.5.1 Regulation of Cell Immunotherapy in China
    • 8.5.2 Legal Requirements and Frameworks in Japan
  • 8.6 Expedited Regulatory Designations Around the World
  • 8.7 Pricing of CAR T-Cell Therapy
  • 8.8 Reimbursement of CAR T-Cell Therapy

9 CAR T-Cell Therapy Development and Manufacturing

  • 9.1 Overview
  • 9.2 Challenges in CAR T-Cell Therapy
    • 9.2.1 Therapy Approval
    • 9.2.2 Manufacture Quality Control
    • 9.2.3 Efficacy and Quality-Adjusted Life-Year (QALY) Assessment
    • 9.2.4 Safety Assessment
    • 9.2.5 Pricing and Patient Access
    • 9.2.6 Reimbursement

10 Market Dynamics

  • 10.1 Impact Analysis
  • 10.2 Market Drivers
    • 10.2.1 Rising Number of Patients with Hematologic Cancers
    • 10.2.2 Dramatic Rise in Global CAR T-Cell Trials
    • 10.2.3 Landmark Approvals of CAR T-Cell Therapies by USFDA and EMA
  • 10.3 Market Restraints
    • 10.3.1 High Treatment Cost of CAR T-Cell Therapy
    • 10.3.2 Side-Effects of CAR T-Cell Therapy
  • 10.4 Market Opportunities
    • 10.4.1 Opportunities for Immunotherapy

11 Global CAR T-Cell Therapy Market (by Application)

  • 11.1 Overview
  • 11.2 Diffuse Large B-Cell Lymphoma (DLBCL)
  • 11.3 Acute Lymphoblastic Leukemia (ALL)
  • 11.4 Multiple Myeloma (MM)
  • 11.5 Chronic Lymphocytic Leukemia (CLL)
  • 11.6 Follicular Lymphoma (FL)
  • 11.7 Mantle Cell Lymphoma (MCL)
  • 11.8 Others

12 Global CAR T-Cell Therapy Market (by Target Antigen)

  • 12.1 Overview
  • 12.2 CD19/CD22
  • 12.3 BCMA (B-Cell Maturation Antigen)
  • 12.4 Other Antigens

13 Global CAR T-Cell Therapy Market (by Region)

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 U.S.
      • 13.2.1.1 U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.2.2 Canada
      • 13.2.2.1 Canada CAR T-Cell Therapy Market (by Application), 2019-2030
  • 13.3 Europe
    • 13.3.1 Germany
      • 13.3.1.1 Germany CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.3.2 U.K.
      • 13.3.2.1 U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.3.3 France
      • 13.3.3.1 France CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.3.4 Italy
      • 13.3.4.1 Italy CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.3.5 Spain
      • 13.3.5.1 Spain CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.3.6 Rest-of-Europe
      • 13.3.6.1 Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
  • 13.4 Asia-Pacific
    • 13.4.1 China
    • 13.4.2 Japan
      • 13.4.2.1 Japan CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.4.3 India
    • 13.4.4 South Korea
    • 13.4.5 Australia
      • 13.4.5.1 Australia CAR T-Cell Therapy Market (by Application), 2019-2030
    • 13.4.6 Rest-of-APAC
      • 13.4.6.1 Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
  • 13.5 Latin America
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest-of-Latin America
  • 13.6 Rest-of-the-World

14 Competitive Landscape

  • 14.1 Key Developments and Strategies
    • 14.1.1 Overview
      • 14.1.1.1 Regulatory and Legal Developments
      • 14.1.1.2 Partnerships, Alliances, and Business Expansions
      • 14.1.1.3 M&A Activities
      • 14.1.1.4 Funding Activities
  • 14.2 Market Share Analysis

15 Company Profiles

  • 15.1 Overview
  • 15.2 Amgen, Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Role of Amgen, Inc. in Global CAR T-Cell Therapy Market
    • 15.2.3 Financials
    • 15.2.4 R&D Expenditure, 2017-2019
    • 15.2.5 SWOT Analysis
  • 15.3 Autolus Therapeutics plc
    • 15.3.1 Company Overview
    • 15.3.2 Role of Autolus Therapeutics plc in Global CAR T-Cell Therapy Market
    • 15.3.3 Financials
    • 15.3.4 R&D Expenditure, 2017-2019
    • 15.3.5 SWOT Analysis
  • 15.4 Bellicum Pharmaceuticals, Inc.
    • 15.4.1 Company Overview
    • 15.4.2 Role of Bellicum Pharmaceuticals, Inc. in Global CAR T-Cell Therapy Market
    • 15.4.3 Financials
    • 15.4.4 R&D Expenditure, 2017-2019
    • 15.4.5 SWOT Analysis
  • 15.5 Bluebird Bio Inc
    • 15.5.1 Company Overview
    • 15.5.2 Role of Bluebird Bio Inc in Global CAR T-Cell Therapy Market
    • 15.5.3 Financials
    • 15.5.4 R&D Expenditure, 2017-2019
    • 15.5.5 SWOT Analysis
  • 15.6 Bristol-Myers Squibb Company
    • 15.6.1 Company Overview
    • 15.6.2 Role of Bristol Myers Squibb Company in Global CAR T-Cell Therapy Market
    • 15.6.3 Financials
    • 15.6.4 R&D Expenditure, 2017-2019
    • 15.6.5 SWOT Analysis
  • 15.7 CARsgen Therapeutics, Ltd.
    • 15.7.1 Company Overview
    • 15.7.2 Role of CARsgen Therapeutics, Ltd. in Global CAR T-Cell Therapy Market
    • 15.7.3 SWOT Analysis
  • 15.8 Cartesian Therapeutics, Inc.
    • 15.8.1 Company Overview
    • 15.8.2 Role of Cartesian Therapeutics, Inc. in Global CAR T-Cell Therapy Market
    • 15.8.3 SWOT Analysis
  • 15.9 Cellectis S.A.
    • 15.9.1 Company Overview
    • 15.9.2 Role of Cellectis S.A. in Global CAR T-Cell Therapy Market
    • 15.9.3 Financials
    • 15.9.4 R&D Expenditure, 2017-2019
    • 15.9.5 SWOT Analysis
  • 15.1 Celyad Oncology SA
    • 15.10.1 Company Overview
    • 15.10.2 Role of Celyad Oncology SA in Global CAR T-Cell Therapy Market
    • 15.10.3 Financials
    • 15.10.4 R&D Expenditure, 2017-2019
    • 15.10.5 SWOT Analysis
  • 15.11 Fortress Biotech, Inc
    • 15.11.1 Company Overview
    • 15.11.2 Role of Fortress Biotech, Inc. in Global CAR T-Cell Therapy Market
    • 15.11.3 Financials
    • 15.11.4 R&D Expenditure, 2017-2019
    • 15.11.5 SWOT Analysis
  • 15.12 Janssen Pharmaceuticals, Inc.
    • 15.12.1 Company Overview
    • 15.12.2 Role of Janssen Pharmaceuticals, Inc in Global CAR T-Cell Therapy Market
    • 15.12.3 Financials
    • 15.12.4 R&D Expenditure, 2017-2019
    • 15.12.5 SWOT Analysis
  • 15.13 Kite Pharma, Inc (A Gilead Company)
    • 15.13.1 Company Overview
    • 15.13.2 Role of Kite Pharma, Inc in Global CAR T-Cell Therapy Market
    • 15.13.3 Financials
    • 15.13.4 R&D Expenditure, 2017-2019
    • 15.13.5 SWOT Analysis
  • 15.14 Legend Biotech Corporation
    • 15.14.1 Company Overview
    • 15.14.2 Role of Legend Biotech Corporation. in Global CAR T-Cell Therapy Market
    • 15.14.3 SWOT Analysis
  • 15.15 Novartis AG
    • 15.15.1 Company Overview
    • 15.15.2 Role of Novartis AG in Global CAR T-Cell Therapy Market
    • 15.15.3 Financials
    • 15.15.4 R&D Expenditure, 2017-2019
    • 15.15.5 SWOT Analysis
  • 15.16 Pfizer Inc.
    • 15.16.1 Company Overview
    • 15.16.2 Role of Pfizer Inc. in Global CAR T-Cell Therapy Market
    • 15.16.3 Financials
    • 15.16.4 R&D Expenditure, 2017-2019
    • 15.16.5 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.